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The aim of this study was to investigate the impact of myocardial ﬁbrosis in Fabry disease.tment o
iversity
Unive
revised
s an op
mons.
ork wa
d Forsc
rted by
eldorf,
rämer a
ge 900
spondin
addres
/14/$ -
hts rese
i.org/1Seventy-three patients with genetically conﬁrmed Fabry disease were followed for 4.8 –
2.4 years. In accordance with current guidelines, 57 patients received enzyme replacement
therapy (ERT) after study inclusion, whereas 16 did not. At baseline and latest possible
follow-up, myocardial ﬁbrosis was assessed noninvasively by cardiac magnetic resonance,
and biomarkers of collagen metabolism were determined. Holter electrocardiography and
clinical follow-up at yearly intervals were used to monitor malignant ventricular arrhyth-
mias (MVAs; nonsustained and sustained ventricular tachycardia and sudden cardiac
death). In total, 48 patients (66%) showed ﬁbrosis assessed by late enhancement (LE) at
baseline, and 4 patients developed new LE during follow-up, 2 of them despite ERT. The 2
patients receiving ERT (1.4 – 1.9% vs 2.5 – 2.6%, p <0.001) and the patients not receiving
ERT (0.5 – 0.8% vs 0.7 – 1.0%, p [ 0.035) showed a progression of LE during follow-up.
None of the patients displayed reductions of LE during follow-up. Collagen biomarkers
were elevated in patients with and without LE but did not correlate with LE amount.
Thirteen LE-positive patients at the baseline examination had documented MVAs
(including 5 sudden cardiac deaths), whereas none of the patients without LE had MVAs.
The yearly increase in ﬁbrosis was 0.9 – 0.6% in patients with MVAs and 0.2 – 0.3% in
patients without MVAs (p <0.001). Logistic multivariate regression analysis revealed that
the annual increase in ﬁbrosis during follow-up was the only independent predictor of
MVAs. In conclusion, myocardial ﬁbrosis in Fabry disease is progressive, apparently not
modiﬁed by ERT, and a crucial outcome determinant.  2014 The Authors. Published by
Elsevier Inc. All rights reserved. (Am J Cardiol 2014;114:895e900)Fabry disease is an X-linked lysosomal storage disorder
caused by a deﬁciency of a-galactosidase A.1 Cardiac
involvement is characterized by the accumulation of globo-
triaosylceramide in cells, causing left ventricular (LV) hy-
pertrophy and ﬁnally leading to myocardial replacement
ﬁbrosis in the hearts of patients with Fabry disease.2 The
dominant cardiac symptoms are arrhythmias and heart fail-
ure, which determine the reduced life expectancy observed in
patients with Fabry disease.3,4 The reference standard for
noninvasively assessing myocardial ﬁbrosis is cardiac mag-
netic resonance (CMR) using the late enhancement (LE)
technique,5,6 and various studies have successfully used this
tool to investigate myocardial ﬁbrosis in patients with
Fabry disease.7e11 Although LE was used to stage patientsf Internal Medicine I and bComprehensive Heart Failure
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0.1016/j.amjcard.2014.06.019with Fabry disease, a prospective longitudinal study to
quantify the development of myocardial ﬁbrosis is lacking,
especially in patients receiving enzyme replacement therapy
(ERT). Moreover, the prognostic relevance of myocardial
ﬁbrosis in Fabry disease needs further evaluation. We hy-
pothesized that the ﬁbrotic progression in the Fabry cardio-
myopathy has an impact on prognosis. Thus, we investigated
the impact of myocardial ﬁbrosis in this disease using CMR
LE imaging and collagen biomarkers and determined the
occurrence of malignant ventricular arrhythmias (MVAs).
Methods
In total, 171 referred patients were screened at their ﬁrst
visits to the Fabry center in Würzburg (Figure 1). All of the
following criteria had to be met for inclusion in this
observational study: (1) genetically proved Fabry disease,
(2) the ability to undergo CMR imaging with contrast agent,
(3) no ERT before this study, (4) no ERT therapy switch
during follow-up, (5) a minimum follow-up time of 1 year
with 2 corresponding CMR scans or death during follow-up,
and (6) informed consent. Overall, 73 consecutive patients
with Fabry disease (35 female) fulﬁlled all these criteria and
were included. Recruitment started in January 2001 and
ended in September 2009. The treatment decision for ERT
was reviewed at study start, and in accordance with current
guidelines,12 57 patients received ERT and 16 did not. In
accordance with the Declaration of Helsinki, written
informed consent from all patients or their guardians waswww.ajconline.org
Figure 1. Flowchart of the complete screened group and the study cohort.
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Several patients from the present study cohort have been
included in other open-cohort studies from our center.
CMR was performed at ﬁrst presentation and latest
possible follow-up with intravenous injection of gadobenate
dimeglumine 0.1 mmol/kg (MultiHance; Bracco Di-
agnostics, Milan, Italy) on a 1.5-T scanner (Magnetom
Symphony Quantum; Siemens Medical Systems, Erlangen,
Germany). Standard steady-state free precession cine breath-
hold short-axis 4-, 3-, and 2-chamber images were used to
determine wall thickness, cardiac mass, and the ejection
fraction. LE images (Figure 2) were acquired with inverse
recovery sequences (slice thickness 8 mm, breath hold, ﬁeld
of view 240  320 mm2, matrix size 165  256, repetition
time 7.5 ms, echo time 3.4 ms, ﬂip angle 25). Care was taken
to use the same settings for the follow-up scan.
The analysis was done blinded to all clinical data by an
experienced CMR specialist (>15 years’ experience in
CMR, >10 years’ experience with Fabry disease). Inter- and
intraobserver variability was recently published by our
group.13
All consecutive short-axis slices were used for measuring
the area with pathologic LE. The sum of areas was multi-
plied by the slice thickness and then set in relation to LV
myocardial volume (the amount of LV ﬁbrosis as a per-
centage). To calculate the percentage change in ﬁbrosis over
time in a single patient, we subtracted the percentage of
ﬁbrosis determined in the last available CMR examination
from the result taken from the baseline CMR examination.
Any CMR examinations performed between these times
points were omitted from the analysis.
Peripheral venous blood samples were obtained after
30 minutes of rest in the supine position at baseline and
latest possible follow-up. Blood samples were immediately
centrifuged at 4C at 10g for 10 minutes. Afterward,aliquots of 100 to 250 ml serum were stored at 20C for
3 days until ﬁnal storage in a freezer at 80C. All ali-
quots were analyzed at the end of the study period. Serum
procollagen type III aminoterminal propeptide, procollagen
type I carboxyterminal propeptide, and collagen type I
carboxyterminal telopeptide levels were quantiﬁed using a
radioimmunoassay technique using commercially available
kits from USCN Life Science Inc. (Wuhan, China), as
previously described.14
The occurrence of MVAs (nonsustained and sustained
ventricular tachycardia [VT] and sudden cardiac death) was
determined in annual intervals by Holter electrocardiog-
raphy of 24 hours in duration (mean 28  5.5 hours). All
available Holter electrocardiograms for each patient were
analyzed for the detection of arrhythmias. Sudden cardiac
death was deﬁned as an unexpected arrest of presumed
cardiac origin within 1 hour after the onset of any symptoms
that could be interpreted as being cardiac in origin.
All values are presented as absolute number (percentage)
or mean  SD. Differences between 2 groups were tested
using paired or unpaired t tests, chi-square tests, or Fisher’s
exact tests, as appropriate. Higher group numbers were
tested using 2-way analysis of variance with Duncan’s post
hoc analysis and Bonferroni’s correction. A Kaplan-Meier
curve was plotted for visualizing the event-free rate of
MVAs of patients with and without ﬁbrosis as indicated by
LE, and a log-rank test was performed to statistically
compare the 2 survival curves. Predictors of MVAs were
sought using logistic regression analysis. The multivariate
regression analysis included percentage LV ﬁbrosis, LV
mass, septal wall thickness, blood pressure, annual increase
of LV mass, and annual increase of percentage LV ﬁbrosis,
all selected on the basis of univariate predictors of MVAs.
The multivariate logistic regression analysis was performed
with ﬁxed adjustment for age, gender, kidney function, and
ERT status. A p value <0.05 or corrected values in multiple
testing were deemed to indicate statistical signiﬁcance. Data
were analyzed using SPSS versions 20 and 21 (SPSS, Inc.,
Chicago, Illinois).
Results
Seventy-three consecutive patients with Fabry disease
were included in this observational study and followed for
4.8  2.4 years. Table 1 lists the general clinical data of the
complete cohort, indicating reasonably preserved kidney and
global LV function and moderate LV hypertrophy. In total,
48 patients (66%) exhibited ﬁbrosis as assessed by LE on
CMR at baseline. Table 2 lists the baseline CMR and
biomarker data, split into groups of patients with and without
ﬁbrosis. There was no difference in the ejection fraction;
however, signiﬁcant differences were seen in LV wall
thickness and LV mass. Collagen biomarkers were elevated
in the 2 groups compared with healthy controls reported in
the published research14 but did not differentiate between
groups. During follow-up, patients with and those without
ERT showed progressive LE, as evidenced by an increase in
percentage LV ﬁbrosis on repeat CMR (Table 3). Those with
ERT showed an increase from 1.4  1.9% at baseline to 2.5
 2.6% at follow-up (p<0.001); those without ERT showed
an increase from 0.5 0.8% to 0.7 1.0% (p¼ 0.035). None
Figure 2. CMR short-axis images of patients with Fabry disease. A male patient with severe LE in the basal posterolateral wall segment (arrow) and
hypertrophy (A) and a female patient without LE (B). LV ¼ left ventricle; RV ¼ right ventricle.
Table 1
Clinical baseline characteristics of the Fabry patients (n ¼ 73)
Male/Female 38/35 (48%/52%)
Age (years) 39  11
Height (cm) 172  10
Weight (kg) 68  13
Heart rate (1/min) 66  14
Systolic blood pressure (mmHg) 123  18
Diastolic blood pressure (mmHg) 81  12
Abnormal sweating 50 (67%)
Heat or cold intolerance 49 (67%)
Chronic diarrhea 30 (41%)
Sudden deafness 18 (25%)
Angiokeratomata 30 (41%)
Dialysis 7 (10%)
Kidney transplantation 6 (8%)
Serum creatinine (mg/dl) 1.5  2.1
Diethylene triamine pentaacetic acid clearance
(ml/min)
93  32
Stroke/transitory ischemic attack 9 (12%)
Typical neuropathic pain 51 (79%)
Chronic pain syndrome 32 (44%)
Depression 11 (15%)
Left-ventricular mass (g/m2) 85  32
Left-ventricular ejection fraction (%) 63  8
Septal wall thickness (mm) 11.3  3.8
Amount of ﬁbrosis (% of left-ventricular mass) 1.2  1.7
Table 2
Cardiac Magnetic Resonance, biomarker results and events of patients with
and without ﬁbrosis
No Fibrosis
(n ¼ 25)
Fibrosis
(n ¼ 48)
Left-ventricular mass (g/m2) 70  16 93  36*
Septal wall thickness (mm) 9.4  2.4 12.2  4.0*
Ejection fraction (%) 62  7 64  9
Amount of ﬁbrosis (% of left-ventricular
mass)
0 1.8  1.8*
Procollagen type I carboxy-terminal
propeptide (ng/ml)
308  399 302  361
Collagen type I carboxy-terminal
telopeptide (ng/ml)
8.3  15.3 8.0  12.9
Procollagen type III amino-terminal
propeptide (mg/l)
5.9  2.4 6.8  3.7
Malignant ventricular arrhythmias 0 (0%) 13 (27%)
Sudden cardiac death 0 (0%) 5 (10%)
* Signiﬁcant vs. “No ﬁbrosis”, p <0.05.
Cardiomyopathy/Cardiac Fibrosis in Fabry Disease 897of the patients showed reductions in LE at follow-up. Four
patients developed new ﬁbroses at rates of þ0.9% after
8 years (no ERT), þ0.7% after 6 years (no ERT), þ1.7%
after 7 years (ERT), and þ1.0% after 5 years (ERT). There
was no signiﬁcant change in any of the biomarkers in either
the ERT-naive or in the ERT group. Results are listed ac-
cording to ERT status in Table 3.
Annually repeated Holter electrocardiography (407 Holter
studies in total, i.e., 4 or 5 per patient) and clinical follow-up
was used to search for MVAs. No patients without LE
showed MVAs during follow-up, whereas 13 patients with
LE experienced MVAs (Table 2). Five of these patients
experienced sudden cardiac death; 1 of those had an
implantable cardioverter-deﬁbrillator (ICD) placed after thedetection of VT and showed multiple adequately terminated
episodes of sustained VT during an in-hospital stay before he
died because of VT; another patient with VT had an ICD
implanted and experienced multiple episodes of sustained
VT adequately terminated by the ICD. The 7 remaining pa-
tients had nonsustained VT. One of these patients with
nonsustained VT was the sixth patient who died. He died
presumably not because of cardiac reasons but because of
sepsis with acute or chronic kidney failure. However, he
presented with LE of 5.2% at latest follow-up and, as stated
earlier, had documented nonsustained VT on Holter elec-
trocardiography. In general, all indications for the implan-
tation of an ICD in patients participating in this study were
based on the documentation of VT during Holter electro-
cardiography to prevent sudden cardiac death.
On Kaplan-Meier analysis for MVAs in the 2 groups (LE
vs no LE), a signiﬁcant difference between the 2 curves
could be observed (log-rank p ¼ 0.017; Figure 3). Logistic
regression analysis revealed that the annual increase in
ﬁbrosis (percentage) during follow-up was the only inde-
pendent predictor of MVAs in our cohort (p ¼ 0.038). The
Table 3
Cardiac Magnetic Resonance and biomarker results of patients with and without Enzyme replacement therapy at baseline and at follow up
No Enzyme Replacement Therapy; Enzyme Replacement Therapy;
Baseline (n ¼ 16) Follow-Up (n ¼ 16) Baseline (n ¼ 57) Follow-Up (n ¼ 56)*
Left-ventricular mass (g/m2) 59  11 61  14 92  33† 90  30z
Septal wall thickness (mm) 8.0  1.6 8.6  1.9 12.2  3.7† 12.3  3.7z
Ejection fraction (%) 60  6 59  8 64  9 63  9
Amount of ﬁbrosis (% of left-ventricular mass) 0.5  0.8 0.7  1.0x 1.4  1.9† 2.5  2.6zx
Procollagen type I carboxy-terminal propeptide (ng/ml) 319  362 194  290 299  377 240  346
Collagen type I carboxy-terminal telopeptide (ng/ml) 9.9  18.4 6.2  14.7 6.2  14.7 9.8  15.0
Procollagen type III amino-terminal propeptide (mg/l) 5.7  1.6 5.9  1.7 5.9  1.7 6.8  3.1
* Only one patient died before he could get a regular follow up with cardiac magnetic resonance and biomarkers.
† Signiﬁcant vs. No ERT, BS; p <0.05.
z Signiﬁcant vs. No ERT, FU; p <0.05.
x Signiﬁcant vs. same group baseline; p <0.05.
Figure 3. Kaplan-Meier survival plot of the occurrence of MVAs in patients
with (grey) and without (black) LE at baseline examination. Note that in the
follow-up time of nearly 5 years, no events occurred in patients without LE
at baseline. Five of the ventricular arrhythmias in the group with LE were
fatal.
898 The American Journal of Cardiology (www.ajconline.org)annual increase in ﬁbrosis was 0.9  0.6% in patients
with MVAs and 0.2  0.3% in patients without MVAs
(p <0.001).
Discussion
Myocardial ﬁbrosis is 1 of the hallmarks of Fabry car-
diomyopathy.2,8,10,11 Clinical and registry data suggest that
patients with Fabry disease may experience MVAs and die
predominantly because of cardiac reasons, but a causal
relation has been hypothetical so far.3,4,15 We conducted the
ﬁrst systematic investigation of the longitudinal quantiﬁca-
tion of cardiac ﬁbrosis via CMR and its relation to cardiac
arrhythmias and clinical events in a large Fabry cohort. The
main ﬁndings are as follows: (1) myocardial ﬁbrosis is a
common feature in Fabry cardiomyopathy; (2) regardless of
ERT, cardiac ﬁbrosis progresses over time, with no possi-
bility of regression; (3) established blood biomarkers for
ﬁbrosis are elevated in patients with Fabry but are not
helpful for either characterizing cardiomyopathy or staging
the disease; and (4) myocardial ﬁbrosis relates to MVA, andsubjects with a high annual increase in LV ﬁbrosis are at risk
for sudden cardiac death.
Gadolinium is an extracellular agent that cannot cross
intact cell membranes.16 Late gadolinium enhancement is an
observed phenomenon that occurs when myocardial damage
is present; T1-weighted LE images can reveal information
useful for the noninvasive assessment of myocardial
ﬁbrosis.16 In early stages, the nonischemic cardiomyopathy
LE distribution pattern mostly spares the subendocardial
region and is limited to the midwall and epicardial regions.16
With disease progression, this pattern can change to trans-
mural LE.11 This nonischemic LE pattern is also charac-
teristic of patients with Fabry cardiomyopathy but typically
starts at the lateral basal region.10,17 Adabag et al18 showed
that LE in hypertrophic cardiomyopathy increases suscep-
tibility to arrhythmias. Recently, 2 independent studies
consistently found that a large amount of LE predicts major
adverse cardiac events in patients with hypertrophic car-
diomyopathy.19,20 According to current hypertrophic car-
diomyopathy guidelines, however, this CMR-derived risk
information does not (yet) establish an indication for ICD
implantation.21
Moon et al8 were the ﬁrst to describe LE as a marker of
myocardial ﬁbrosis in patients with Fabry disease. Subse-
quently, it became evident that LE starts in the posterolateral
wall in Fabry cardiomyopathy.2,7e11,16,22 Treatment studies
showed that the recovery of regional myocardial function and
the regression of LV wall thickness depend on the extent of
LE at the initiation of ERT.10 In patients with high LE burden,
only a stabilization of regional LV function and a mild
beneﬁcial decrease in septal wall thickness were observed.10
The present data strongly suggest that the development of
myocardial ﬁbrosis cannot be stopped or reversed by ERT. In
contrast, the amount of ﬁbrosis in relation to the LV
myocardial volume doubled in the course of 5 years in our
study, despite ERT. The fact that none of the ERT-treated
patients showed a reduction in the amount of ﬁbrosis might
indicate that Fabry cardiomyopathy, and perhaps Fabry dis-
ease in general, is a progressive ﬁbrotic disease, starting early
in patients’ lives and progressively worsening over time. This
hypothesis is also supported by data on collagen biomarkers,
which exhibit elevated levels in the groups with and without
LE. The fact that patients receiving ERT showed a greater LE
Figure 4. A typical echocardiographic 4-chamber view of a patient with Fabry disease (A) with left ventricular hypertrophy, a prominent papillary muscle, and
wall thinning lateral. (B) The corresponding CMR image with LE (the arrow indicates the ﬁbrotic area in the inferolateral wall). In this patient, nonsustained
ventricular arrhythmia was documented (C) during annual follow-up (Holter electrocardiography), and an ICD was implanted. LV ¼ left ventricle; RV ¼ right
ventricle.
Cardiomyopathy/Cardiac Fibrosis in Fabry Disease 899increase over time in comparison with patients not receiving
ERT might indicate that the ﬁbrotic remodeling is worsened
or accelerated in sicker patients.
In 2005, Shah et al15 were the ﬁrst to publish that ven-
tricular arrhythmias might affect the outcomes of patients
with Fabry disease. In addition, it was shown that the causes
of death in patients with Fabry disease are dominated by
cardiac causes, namely, sudden cardiac death, since kidney
replacement therapy has become widely available.3,4 Higa-
shi et al23 suggested that the origin of ventricular arrhythmia
might be the posterolateral basal wall, that is, the area where
LE usually originates. This morphologic-electrical interac-
tion theory ﬁts very well with the present ﬁnding that pa-
tients with Fabry disease with LE and high annual increases
of ﬁbrotic burden are prone to MVAs and are at risk for
sudden cardiac death. Findings for a typical patient with LE
and an MVA are shown in Figure 4.
Fabry guidelines recommend echocardiography as the
imaging technique of choice when evaluating a patient for
cardiac involvement.12 However, because only CMR can
detect cardiac ﬁbrosis, this technique should be used to
document or rule out clinically relevant LE. In hearts
without LE, MVAs are very unlikely to occur. As soon
as LE is detected, careful clinical monitoring for MVA is
required. Especially in hearts with large LE-positive areas,
annual Holter electrocardiography, as recommended by
current guidelines,12 might not sufﬁce, and advanced tech-
niques such as an event recorder should be considered. In
addition, our data corroborate the view that as soon as
MVAs are detected in “ﬁbrotic hearts,” an ICD should be
implanted to prevent sudden cardiac death. The present datafurther suggest that every ﬁbrotic heart in a patient with
Fabry disease is at risk for MVA as soon as a speciﬁed
amount of ﬁbrosis is exceeded. To recommend the im-
plantation of an ICD without documentation of MVA,
further studies are required. We recommend regular moni-
toring of those patients at risk for arrhythmias and suggest
the implantation of an event recorder.
Another very important fact must be considered when
following patients with Fabry over time: even with ERT,
patients can develop new LE, thus mandating a regular
CMR monitoring algorithm. In addition, patients who are
already LE positive at the initiation of ERT may progress to
advanced ﬁbrotic cardiomyopathy stages, requiring exten-
sion of therapy. This is emphasized by the fact that the only
independent predictor of MVA in our cohort was the annual
increase in ﬁbrotic burden. Thus, patients who were LE
negative at baseline also require follow-up magnetic reso-
nance imaging.
The analysis of collagen markers in our work did not
result in clear ﬁndings in patients with hypertrophic car-
diomyopathy, such as those provided in the work of, for
example, Ho et al.24 This might partly be because Fabry
disease can be regarded as a “general” ﬁbrotic disease,
meaning that not only the heart but also the kidneys and
other organs might be involved in the ﬁbrotic process.
Reduced kidney function might also play a role in collagen
marker clearance.
In recent years, it has become evident that a 24-hour
Holter electrocardiography once a year might not be sufﬁ-
cient for monitoring patients with Fabry disease. Thus, with
the methods used, we might have missed some MVAs.
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